Abstract
Low to moderate alcohol intake has been associated with beneficial effects on the heart and the vasculature, including improvements in several established and emerging cardiovascular disease (CVD) risk factors as well as reduced risk for several metabolic diseases, CVD morbidity and mortality. Binge and heavy drinking exert the opposite effects, leading to increased risks for all the above conditions. With regard to beverage type, there is some evidence supporting red wine superiority in cardioprotection, although other beverages have also been reported to exert beneficial metabolic and vascular effects when consumed in moderate amounts.
In this narrative review we discuss the associations between alcohol consumption and CVD morbidity and mortality. Alcohol-induced effects on established and emerging CVD risk factors are also discussed taking into consideration different drinking patterns. Physicians should screen for excessive alcohol use and advise individuals to limit their alcohol intake to moderate amounts (up to 20-30 g/day for men and 10-20 g/day for women), preferably consumed with meals. The question of whether alcohol intake should be encouraged as a measure to prevent CVD remains unanswered.
Keywords: Alcohol, cardiovascular disease, cardiovascular risk factors, diabetes, lipids, metabolic syndrome, statins.
Current Pharmaceutical Design
Title:Alcohol and the Cardiovascular System: A Double-Edged Sword
Volume: 20 Issue: 40
Author(s): Niki Katsiki, Konstantinos Tziomalos and Dimitri P. Mikhailidis
Affiliation:
Keywords: Alcohol, cardiovascular disease, cardiovascular risk factors, diabetes, lipids, metabolic syndrome, statins.
Abstract: Low to moderate alcohol intake has been associated with beneficial effects on the heart and the vasculature, including improvements in several established and emerging cardiovascular disease (CVD) risk factors as well as reduced risk for several metabolic diseases, CVD morbidity and mortality. Binge and heavy drinking exert the opposite effects, leading to increased risks for all the above conditions. With regard to beverage type, there is some evidence supporting red wine superiority in cardioprotection, although other beverages have also been reported to exert beneficial metabolic and vascular effects when consumed in moderate amounts.
In this narrative review we discuss the associations between alcohol consumption and CVD morbidity and mortality. Alcohol-induced effects on established and emerging CVD risk factors are also discussed taking into consideration different drinking patterns. Physicians should screen for excessive alcohol use and advise individuals to limit their alcohol intake to moderate amounts (up to 20-30 g/day for men and 10-20 g/day for women), preferably consumed with meals. The question of whether alcohol intake should be encouraged as a measure to prevent CVD remains unanswered.
Export Options
About this article
Cite this article as:
Katsiki Niki, Tziomalos Konstantinos and Mikhailidis P. Dimitri, Alcohol and the Cardiovascular System: A Double-Edged Sword, Current Pharmaceutical Design 2014; 20 (40) . https://dx.doi.org/10.2174/1381612820666140620125741
DOI https://dx.doi.org/10.2174/1381612820666140620125741 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Taurine-Diabetes Interaction: From Involvement to Protection
Current Diabetes Reviews Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Molecular Genetics of Left Ventricular Dysfunction
Current Molecular Medicine Disruption of Circadian Rhythms and Sleep on Critical Illness and the Impact on Cardiovascular Events
Current Pharmaceutical Design Focal Adhesion Kinase: From In Vitro Studies to Functional Analyses In Vivo
Current Protein & Peptide Science Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Thyroid Disorders in Chronic Heart Failure: From Prognostic Set-up to Therapeutic Management
Endocrine, Metabolic & Immune Disorders - Drug Targets Toll-Like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms
Current Genomics Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Pulmonary Hypertension and Systemic Diseases
Current Drug Targets - Inflammation & Allergy Manoyl-Oxide Biotransformations with Filamentous Fungi
Current Organic Chemistry Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology Mechanisms Explaining the Influence of Subclinical Hypothyroidism on the Onset and Progression of Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions
Current Medicinal Chemistry Heat Shock Proteins: Mediators of Atherosclerotic Development
Current Drug Targets Cell Therapy for the Treatment of Chronic Ischemic Heart Disease
Current Pharmaceutical Design Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine The Role of Circadian Rhythms in Fatal Arrhythmias and the Potential Impact of Intervention for Sleep-Disordered Breathing
Current Pharmaceutical Design